북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 최종 용도별, 국가별, 부문별 예측(2024-2030년)

North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030

US $ 4,950 ￦ 6,946,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950 ￦ 8,350,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 7,950 ￦ 11,157,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 규모는 2030년까지 168억 1,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 5.13% 성장할 것으로 예상됩니다.

더 나은 ROI로 새로운 분자를 출시하기 위한 경쟁이 치열해짐에 따라 전 세계적으로 CRO 서비스 제공업체에 대한 수요가 증가할 것으로 예상됩니다. 제약사들은 연구 비용의 증가와 함께 규제의 복잡성에 직면하고 있으며, 다양한 포트폴리오에 대한 전문 지식이 필요해지면서 시장에서 아웃소싱에 대한 필요성이 증가하고 있습니다. 임상시험의 민영화가 진행되면서 핵심 기능에 집중하기 위해 CRO 및 CDMO에 대한 아웃소싱이 증가하고 있습니다. 제약 및 생명공학 기업들은 복잡하고 엄격한 일정 관리가 필요한 R&D 업무를 아웃소싱하기 시작했습니다. CRO의 기능은 고객이 제시한 일정에 따라 신제품을 시장에 출시하는 것입니다. CRO는 필요한 인프라와 숙련된 전문 지식을 보유하고 있으며 비용, 시간 및 효율성과 관련된 몇 가지 이점을 제공합니다. 절감된 비용은 스폰서와 환자에게 최고의 비용 절감을 제공하는 데 도움이 됩니다.

약물 발견과 의약품 개발은 제약회사와 생명공학기업이 채택하는 필수적인 전략입니다. 만성질환과 장기질환의 증가는 의약품 개발 과정에서 광범위한 연구개발 투자에 대한 수요 증가로 이어졌습니다. 임상시험 실패율의 증가는 의약품 개발 비용의 증가와 함께 제조업체의 막대한 수익 손실로 이어집니다. 임상시험의 실패는 중소 제약회사들의 파산으로 이어졌습니다. 많은 비상장기업들은 신약개발 과정에 차질이 생기면 벤처 캐피털의 지원을 받을 수 없다고 판단하고 있습니다. 이러한 상황을 피하고 실질적인 투자 수익률을 얻기 위해 제약 회사는 현재 전통적인 임상시험 방법 대신 계산 생물학에 기반한 예측 모델을 채택하여 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 전문가, R&D 임원 및 임상 전문가로부터 얻은 인사이트는 기업이 R&D에 투자할 수 있는 막대한 비용을 절감하는 데 도움이 되며, 이는 컨설팅 서비스에 대한 수요를 증가시킬 것입니다.

최근 헬스케어 아웃소싱 업계에서 M&A가 급증하고 있습니다. 이 분야의 급격한 성장과 유망한 잠재력은 제약회사, 생명공학 기업, 벤처 캐피탈로부터 많은 투자를 유치하고 있습니다. 이에 따라 기업들은 전략적 인수를 통해 자사의 포트폴리오와 역량을 확장하고 새로운 비즈니스 기회를 활용하여 시장 경쟁력을 강화하고자 합니다. 예를 들어, 2024년 5월, 잘트리우스 AG는 엔비디아와의 협업을 발표하며 엔비디아의 AI 기반 컴퓨팅 소프트웨어와 플랫폼을 활용하여 새로운 치료법 개발을 지원하기로 했습니다. 또한, 치료제 개발에 수반되는 복잡성과 높은 비용으로 인해 업계 내 협업과 통합이 증가하고 있으며, M&A는 기업에 보완적인 기술, 전문 지식 및 리소스를 제공하여 개발 과제를 극복하고, 제품 개발 기간을 단축하며, 제조 역량을 강화할 수 있도록 돕습니다.

북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 보고서 하이라이트

• 서비스별로는 컨설팅 분야가 2023년 가장 큰 매출 비중을 차지했습니다.이 분야의 성장 배경에는 규제 준수, 품질 보증, 개선 과제, 스폰서의 전략적 컨설팅 요구 사항을 충족하기 위해 컨설팅 서비스 채택이 확대되고 있는 것이 주요 요인으로 꼽힙니다. 또한, 부정 사례의 증가, 지적재산권(IPR) 불일치, 기술 혁신의 증가 등 제약 및 생명공학 기업이 직면한 주요 도전과제로 인해 규제 컨설팅 서비스가 널리 활용되고 있습니다. 컨설팅 서비스 수요를 촉진하는 또 다른 요인은 시장 통합으로, 합작투자, 인수 및 합병이 증가하면서 시장 통합이 가속화되고 있습니다. 이러한 요인들은 시장 성장을 촉진할 것으로 예상됩니다.
• 최종 용도별로 보면 제약 기업 부문은 2023년 57.79% 이상의 가장 큰 매출 점유율을 차지했습니다.CRO 및 CMO에 대한 아웃소싱은 CRO 및 CMO에 대한 아웃소싱은 제약사가 자체적으로 대규모 역량을 보유하는 것보다 비용 효율적인 솔루션을 제공하기 때문에 이 부문의 매출 성장을 견인할 것으로 예상됩니다. 비용 효율적인 솔루션을 제공합니다.
• 바이오테크놀러지 및 제약 서비스 아웃소싱 시장에서 미국은 2023년 87.37%의 점유율을 차지했습니다.미국의 매출 성장은 임상시험에 대한 높은 R&D 비용에 기인하며, 이는 시장 성장을 촉진할 것으로 예상되는 주요 요인으로 작용할 것으로 보입니다. 예를 들어, 2021년 10월 미국 FDA는 11개의 새로운 임상시험 연구를 승인했으며, 그 결과 향후 4년간 2,500만 달러 이상의 자금이 지원될 예정입니다. 이 보조금은 희귀 질환 치료에 특화된 새로운 의료 제품 개발을 지원하는 것을 목표로 하고 있습니다. 의약품 수요 증가에 대응하기 위해 제조 능력을 확대하는 이들 기업의 존재감이 커지고 있으며, 이는 시장 성장을 촉진할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
• 테크놀러지 상황
• 가격 모델 분석
• GxP 개요
• 임상시험 볼륨 분석(2023년)
• R&D 투자 분석
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 분석 툴
• COVID-19의 영향 분석

제4장 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 서비스별 추정·동향 분석

• 부문 대시보드
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 서비스별 변동 분석
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 규모와 동향 분석, 서비스별, 2018-2030년
• 컨설팅
• 규제 관련 업무
• 제품 설계와 개발
• 감사와 평가
• 제품 유지보수
• 트레이닝과 교육
• 기타

제5장 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 최종 용도별 변동 분석
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 제약회사
• 바이오테크놀러지 기업

제6장 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 국가별 추정·동향 분석, 서비스별, 최종 용도별

• 국가별 대시보드
• 북미의 바이오테크놀러지 및 제약 서비스 아웃소싱 시장 : 국가별 변동 분석
• 미국
• 캐나다
• 멕시코
• 푸에르토리코

제7장 경쟁 상황

• 기업 분류
  • 시장 리더
  • 신흥 기업
• 기업 시장 점유율/평가 분석, 2023년
• 서비스 히트맵 분석
• 기업 개요
  • Parexel International Corporation
  • The Quantic Group
  • IQVIA
  • Lachman Consultant Services, Inc.
  • GMP Pharmaceuticals Pty Ltd.
  • LabCorp
  • Charles River Laboratories
  • ICON plc.
  • Syneos Health
  • Lonza
  • Catalent Inc.
  • Samsung Biologics

ksm

영문 목차

영문목차

North America Biotechnology and Pharmaceutical Services Outsourcing Market Growth & Trends:

The North America biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 16.81 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 5.13% from 2024 to 2030.

Increasing competition to launch novel molecules with better RoI is expected to heighten the demand for CRO service providers across the globe. Pharmaceutical companies face complexity in regulations along with increased research costs, creating a need for expertise in numerous portfolios and driving the need for outsourcing in the market. With increasing clinical trial privatization, there has been an increase in outsourcing functions to CROs and CDMOs to focus on core capabilities. Pharmaceutical and biotechnology companies have started outsourcing R&D activities, which are complex and need a strict timeline to follow up. A CRO's function is to bring new products to the market as per the timeline given by the client. CROs have the required infrastructure and skilled expertise, which provides several advantages associated with cost, time, and efficiency. The cost saved helps in offering the best savings for sponsors and patients.

Drug discovery and development is an integral strategy adopted by pharmaceutical and biotechnology companies. An increase in the prevalence of chronic and long-term diseases led to a rise in the demand for extensive R&D investments in the drug development process. Growing clinical trial failure rates coupled with increasing drug development costs lead to huge losses in revenue for manufacturers. Setbacks faced in clinical studies have led smaller pharmaceutical companies to go bankrupt. Many private investors have been observed to withdraw venture capital support from startup drug companies, considering their investments would suffer if there were a disruption in the drug development process. To circumvent these situations and gain a substantial return on investment, pharmaceutical companies are now adopting computational biology-based predictive models over traditional methods of clinical trials, which are expected to drive market growth during the forecast period. Insights gained from subject-matter experts, R&D executives, and clinical professionals help a company save a large amount, which can be spent on R&D, thereby boosting demand for consulting services.

The healthcare outsourcing industry has recently witnessed a surge in mergers and acquisitions. The sector's rapid growth and promising potential have attracted significant investment from pharmaceutical companies, biotech firms, & venture capitalists. As a result, companies seek to expand their portfolios and capabilities through strategic acquisitions to capitalize on emerging opportunities and strengthen their competitive position in the market. For instance, in May 2024, Sartorius AG announced a collaboration with NVIDIA to help the development of new therapies, leveraging NVIDIA's AI-powered computing software and platform. Moreover, the complexity and high costs associated with developing therapeutics are leading to increased collaboration & consolidation within the industry. Mergers & acquisitions offer companies complementary technologies, expertise, and resources, enabling them to overcome development challenges, accelerate product development timelines, and enhance manufacturing capabilities.

North America Biotechnology And Pharmaceutical Services Outsourcing Market Report highlights

• Based on service, the consulting segment held the largest revenue share in 2023. The large segment growth is owing to the growing adoption of consulting services to meet regulatory compliance, quality assurance, remediation challenges, and strategic consulting requirements by sponsors. Furthermore, regulatory consulting services are widely used owing to increasing fraud cases, discrepancies in Intellectual Property Rights (IPR), and rising technological innovation, which are some of the major challenges faced by pharmaceutical and biotechnology companies. Another factor driving the demand for consulting services is the consolidated nature of the market, which leads to an increase in the number of joint ventures, takeovers, acquisitions, and mergers. Such factors are anticipated to drive the market growth.
• Based on end use, the pharmaceutical companies segment held the largest revenue share of over 57.79% in 2023. The segment growth is owing to an increasing preference for outsourcing non-core activities such as clinical trials, data management, regulatory compliance, and manufacturing to CROs and CMOs among pharmaceutical companies is anticipated to boost segment revenue growth. Outsourcing to CROs and CMOs provides pharmaceutical companies with cost-effective solutions compared to maintaining extensive in-house capabilities.
• The U.S. dominated the biotechnology and pharmaceutical services outsourcing market with a share of 87.37% in 2023. The country's revenue growth is owing to high R&D spending on clinical trials, which is another major factor expected to fuel market growth. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next four years. These grants aim to support the development of new medical products specifically for treating rare diseases. The growing presence of these companies expanding their manufacturing capabilities to cater to the rising demand for pharmaceuticals is anticipated to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Country-wise Market Calculation
  • 1.7.1. Country Wise Market: Base Estimates
  • 1.7.2. CAGR Calculation
  • 1.7.3. Country Based Segment Share Calculation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis (Model 1)
  • 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
  • 1.8.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.8.4. Bottom-up Approach (Model 4)
• 1.9. Research Scope and Assumptions
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. List of Abbreviations
• 1.13. Objectives
  • 1.13.1. Objective 1
  • 1.13.2. Objective 2
  • 1.13.3. Objective 3
  • 1.13.4. Objective 4

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Outsourcing of R&D Activities
    • 3.2.1.2. Changing Regulatory Landscape
    • 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
    • 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
    • 3.2.1.5. Increasing Mergers and Collaborations
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Monitoring Issues and Lack of Standardization
    • 3.2.2.2. Loss of Control
    • 3.2.2.3. Data Security Issues
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. GxP Overview
  • 3.5.1. Good Manufacturing Practices (GMP)
  • 3.5.2. Current Good Manufacturing Practices (cGMP)
  • 3.5.3. Good Laboratory Practices (GLP)
  • 3.5.4. Good Clinical Practices (GCP)
  • 3.5.5. Good Distribution Practices (GDP)
• 3.6. Clinical Trials Volume Analysis (2023)
  • 3.6.1. Total Number of Clinical Trials, by Country
  • 3.6.2. Total Number of Clinical Trials, by Phase
  • 3.6.3. Total Number of Clinical Trials, by Study Design
  • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area
• 3.7. R&D Investment Analysis
• 3.8. North America Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
  • 3.8.1. Porter's Five Forces Analysis
  • 3.8.2. PESTEL Analysis
• 3.9. COVID-19 Impact Analysis

Chapter 4. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
• 4.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Consulting
  • 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Regulatory Consulting
    • 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Clinical Development Consulting
    • 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Strategic Planning & Business Development Consulting
    • 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Quality Management Systems Consulting
    • 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Regulatory Affairs
  • 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Legal Representation
    • 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Regulatory Writing & Publishing
    • 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Product Registration & Clinical Trial Applications
    • 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Regulatory Submissions
    • 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Regulatory Operations
    • 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Product Design & Development
  • 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Research, Strategy, & Concept Generation
    • 4.6.2.1. Research, Strategy, & Concept Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Concept & Requirements Development
    • 4.6.3.1. Concept & Requirements Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Detailed Design & Process Development
    • 4.6.4.1. Detailed Design & Process Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Design Verification & Validation
    • 4.6.5.1. Design Verification & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.6. Process Validation & Manufacturing Transfer
    • 4.6.6.1. Process Validation & Manufacturing Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.7. Production & Commercial Support
    • 4.6.7.1. Production & Commercial Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Auditing and Assessment
  • 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. General Auditing
    • 4.7.2.1. General Auditing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. Gap Assessments
    • 4.7.3.1. Gap Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.4. Due Diligence Assessments
    • 4.7.4.1. Due Diligence Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.5. Mock Audits/Inspections
    • 4.7.5.1. Mock Audits/Inspections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.6. Inspection/Audit Management and Support
    • 4.7.6.1. Inspection/Audit Management and Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.7. Others
    • 4.7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Product Maintenance
  • 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Training & Education
  • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
• 5.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
• 5.4. Pharmaceutical Companies
  • 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biotech Companies
  • 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Estimates & Trend Analysis, by Service, by End-Use

• 6.1. Country Dashboard
• 6.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Movement Analysis
• 6.3. U.S.
  • 6.3.1. Key Country Dynamics
  • 6.3.2. Competitive Scenario
  • 6.3.3. Regulatory Framework
  • 6.3.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Canada
  • 6.4.1. Key Country Dynamics
  • 6.4.2. Competitive Scenario
  • 6.4.3. Regulatory Framework
  • 6.4.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Mexico
  • 6.5.1. Key Country Dynamics
  • 6.5.2. Competitive Scenario
  • 6.5.3. Regulatory Framework
  • 6.5.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Puerto Rico
  • 6.6.1. Key Country Dynamics
  • 6.6.2. Competitive Scenario
  • 6.6.3. Regulatory Framework
  • 6.6.4. Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
  • 7.1.1. Market Leaders
  • 7.1.2. Emerging Players
• 7.2. Company Market Share/Assessment Analysis, 2023
• 7.3. Service Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Parexel International Corporation
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Service Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. The Quantic Group
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Service Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. IQVIA
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Service Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Lachman Consultant Services, Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Service Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. GMP Pharmaceuticals Pty Ltd.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Service Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. LabCorp
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Service Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Charles River Laboratories
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Service Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. ICON plc.
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Service Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Syneos Health
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Service Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Lonza
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Service Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Catalent Inc.
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Service Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. Samsung Biologics
    • 7.4.12.1. Company Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Service Benchmarking
    • 7.4.12.4. Strategic Initiatives

관련자료